πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated β€” grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≀24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β€” use filters for patent-cliff planning.

Page 105 of 173

  1. US 8709417

    Combination immunotherapy for the treatment of cancer

    Expires Mon Apr 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8709391

    Family of pain producing substances and methods to produce novel analgesic drugs

    Expires Mon Apr 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8709430

    Cancer treatment kits comprising therapeutic antibody conjugates that bind to aminophospholipids

    Expires Mon Apr 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8709464

    Porous objects having immobilized encapsulated biomolecules

    Expires Mon Apr 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8703730

    Complement antagonists and uses thereof

    Expires Mon Apr 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8703920

    Fully human antibodies against N-cadherin

    Expires Mon Apr 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8703136

    Complement inhibition for improved nerve regeneration

    Expires Mon Apr 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8703756

    Synthetic procedure and cancer treatment with cisplatin derivatives

    Expires Mon Apr 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8703751

    Androstenediol as an indicator for assessing estrogenicity

    Expires Mon Apr 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8703200

    Inhibition of neovascularization by cerium oxide nanoparticles

    Expires Mon Apr 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8703134

    Targeted cryptosporidium biocides

    Expires Mon Apr 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8703140

    Inhibition of factor B, the alternative complement pathway and methods related thereto

    Expires Mon Apr 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8697079

    IgE antibodies for the treatment of cancer

    Expires Mon Apr 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8697853

    TAL effector-mediated DNA modification

    Expires Mon Apr 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8697848

    Method for reducing immunogenicity of therapeutic protein compositions

    Expires Mon Apr 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8697709

    Fused ring heteroaryl kinase inhibitors

    Expires Mon Apr 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8697628

    Methods of using AMPD2 inhibitors for the treatment of fatty liver, obesity and diabetes

    Expires Mon Apr 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8697407

    Compositions and methods for inhibiting MMSET

    Expires Mon Apr 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8697348

    Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571

    Expires Mon Apr 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8697081

    Method of modulating neovascularization

    Expires Mon Apr 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8697082

    Prevention and treatment of synucleinopathic and amyloidogenic disease

    Expires Mon Apr 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8697060

    Treatment method for relapsing-remitting multiple sclerosis

    Expires Mon Apr 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8697034

    Hyperpolarized 89-yttrium and methods relating thereto

    Expires Mon Apr 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8697836

    Composition and method for inducing and enhancing a telomerase reverse transcriptase-reactive cytotoxic T lymphocyte response

    Expires Mon Apr 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8697375

    In vivo biofilm infection diagnosis and treatment

    Expires Mon Apr 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8691184

    Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same

    Expires Mon Apr 03 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8691204

    Synthetic diblock copolypeptide hydrogels for use in the central nervous system

    Expires Mon Apr 03 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8691768

    Methods of determining delta opioid receptor subtypes

    Expires Mon Apr 03 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8691195

    Peptide having activity of transforming growth factor and production method therefor

    Expires Mon Apr 03 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8685406

    Compositions of and method of using heat shock protein peptides

    Expires Mon Mar 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8685372

    Peptides and aptamers for targeting of neuron or nerves

    Expires Mon Mar 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8685403

    Insulin-like growth factor signaling and integrin

    Expires Mon Mar 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8686045

    Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics

    Expires Mon Mar 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8686012

    Stem cell differentiating agents and uses therefor

    Expires Mon Mar 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8685929

    Detecting CYP24 expression level as a marker for predisposition to cancer

    Expires Mon Mar 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8685926

    Compositions and method for CaMKII inhibitors and uses thereof

    Expires Mon Mar 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8679510

    Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia

    Expires Mon Mar 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8680132

    Spiro-oxindole MDM2 antagonists

    Expires Mon Mar 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8680094

    1, 4-benzoxazine compounds and derivatives thereof as therapeutic drugs for the treatment of neurodegenerative conditions

    Expires Mon Mar 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8680083

    Controlled release corticosteroid compositions and methods for the treatment of otic disorders

    Expires Mon Mar 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8680058

    Selectively targeted antimicrobial peptides and the use thereof

    Expires Mon Mar 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8680082

    Controlled release corticosteroid compositions and methods for the treatment of otic disorders

    Expires Mon Mar 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8680291

    Diarylhydantoin compounds

    Expires Mon Mar 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8679476

    Interferon-Ξ² production modulating Listeria strains and methods for using same

    Expires Mon Mar 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8679545

    Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract

    Expires Mon Mar 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8673897

    Benzodiazepinone compounds and methods of treatment using same

    Expires Mon Mar 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8673300

    Therapeutic compositions and methods for the prevention of autoimmune diseases

    Expires Mon Mar 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8673301

    YKL-40 monoclonal antibody

    Expires Mon Mar 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.